Complete financial analysis of BioVie Inc. (BIVI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioVie Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- RXR Acquisition Corp. (RXRAU) Income Statement Analysis – Financial Results
- R&D Computer Co.,Ltd. (3924.T) Income Statement Analysis – Financial Results
- SINERGI MULTI LESTARINDO (SMLE.JK) Income Statement Analysis – Financial Results
- PT Agung Semesta Sejahtera Tbk (TARA.JK) Income Statement Analysis – Financial Results
- Northamerican Energy Group Corporation (NNYR) Income Statement Analysis – Financial Results
BioVie Inc. (BIVI)
About BioVie Inc.
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 229.38K | 266.84K | 237.42K | 229.38K | 229.38K | 229.38K | 229.38K | 229.38K | 51.04K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -229.38K | -266.84K | -237.42K | -229.38K | -229.38K | -229.38K | -229.38K | -229.38K | -51.04K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 23.10M | 33.30M | 17.26M | 133.19M | 1.15M | 1.01M | 370.85K | 466.35K | 37.90K | 4.20K | 49.42K | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.26M | 1.77M | 857.88K | 343.09K | 229.18K | 272.97K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.85M | 11.55M | 9.77M | 4.64M | 1.31M | 1.26M | 1.77M | 857.88K | 343.09K | 229.18K | 272.97K | 70.06K |
| Other Expenses | 0.00 | 229.38M | 229.38K | 229.38K | 229.38K | 229.38K | 229.38K | 229.38K | 51.04K | 212.71K | 247.08K | 0.00 |
| Operating Expenses | 31.95M | 45.08M | 27.25M | 138.05M | 2.69M | 2.50M | 2.37M | 1.55M | 432.03K | 233.38K | 322.39K | 70.06K |
| Cost & Expenses | 32.18M | 45.08M | 27.25M | 138.05M | 2.69M | 2.50M | 2.37M | 1.55M | 432.03K | 233.38K | 322.39K | 70.06K |
| Interest Income | 1.14M | 562.26K | 44.08K | 21.97K | 234.00 | 1.16K | 4.00 | 14.00 | 186.00 | 369.00 | 489.00 | 20.00 |
| Interest Expense | 2.89M | 4.30M | 2.16M | 559.46K | 4.77M | 273.00 | 40.96K | 0.00 | 81.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 229.38K | 266.84K | 237.42K | 229.38K | 229.38K | 229.38K | 229.38K | 229.38K | 51.04K | 369.00 | 489.00 | 70.06K |
| EBITDA | -31.95M | -45.69M | -23.68M | -137.80M | -2.46M | -2.27M | -2.14M | -1.32M | -380.81K | -233.01K | -321.90K | 20.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -32.18M | -45.08M | -27.25M | -138.05M | -2.69M | -2.50M | -2.37M | -1.55M | -432.03K | -233.38K | -322.39K | -70.06K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 59.05K | -5.18M | 1.17M | 7.80M | -13.98M | 52.29K | -40.96K | 222.94K | 105.00 | 369.00 | 489.00 | 20.00 |
| Income Before Tax | -32.12M | -50.26M | -26.08M | -130.25M | -16.68M | -2.44M | -2.41M | -1.33M | -431.92K | -233.01K | -321.90K | -70.04K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 4.30M | -3.29M | 559.46K | 4.77M | -51.40K | -1.00 | -222.93K | -105.00 | -369.00 | -489.00 | 20.00 |
| Net Income | -32.12M | -50.26M | -26.08M | -183.85M | -33.78M | -2.49M | -2.43M | -1.33M | -431.92K | -233.01K | -321.90K | -70.04K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -7.30 | -15.47 | -10.58 | -148.23 | -68.52 | -9.82 | -31.77 | -18.61 | -6.19 | -3.34 | -4.62 | 0.00 |
| EPS Diluted | -7.30 | -15.50 | -10.60 | -148.23 | -68.52 | -9.82 | -31.77 | -18.61 | -6.19 | -3.34 | -4.62 | 0.00 |
| Weighted Avg Shares Out | 4.52M | 3.24M | 2.46M | 1.24M | 492.00K | 253.00K | 76.00K | 71.00K | 69.00K | 69.00K | 69.00K | 32.98K |
| Weighted Avg Shares Out (Dil) | 4.52M | 3.25M | 2.47M | 1.24M | 492.95K | 253.96K | 76.61K | 71.51K | 69.76K | 69.77K | 69.67K | 32.98K |
Contact Levi & Korsinsky by March 19, 2024 Deadline to Join Class Action Against BioVie Inc. (BIVI)
NEW YORK, NY / ACCESSWIRE / March 15, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more...
Shareholders that lost money on BioVie Inc.(BIVI) should contact Levi & Korsinsky about pending Class Action - BIVI
NEW YORK , March 15, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in BioVie Inc. ("BioVie" or the "Company") (NASDAQ: BIVI) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of BioVie investors...
Shareholders that lost money on BioVie Inc.(BIVI) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
NEW YORK, NY / ACCESSWIRE / March 15, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more...
March 19, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against - BIVI
NEW YORK, NY / ACCESSWIRE / March 15, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more...
Investors in BioVie Inc. Should Contact Levi & Korsinsky Before March 19, 2024 to Discuss Your Rights - BIVI
NEW YORK, NY / ACCESSWIRE / March 14, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more...
Shareholders of BioVie Inc. Should Contact Levi & Korsinsky Before March 19, 2024 to Discuss Your Rights - BIVI
NEW YORK, NY / ACCESSWIRE / March 14, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more...
The Gross Law Firm Notifies Shareholders of BioVie Inc. (BIVI) of a Class Action Lawsuit and an Upcoming Deadline
NEW YORK , March 14, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of BioVie Inc.. Shareholders who purchased shares of BIVI during the class period listed are encouraged to contact the firm regarding possible lead...
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of BioVie Inc. (BIVI) Shareholders
NEW YORK, NY / ACCESSWIRE / March 14, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more...
Levi & Korsinsky Reminds BioVie Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 19, 2024 - BIVI
NEW YORK, NY / ACCESSWIRE / March 14, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more...
Investors in BioVie Inc. Should Contact Levi & Korsinsky Before March 19, 2024 to Discuss Your Rights - BIVI
NEW YORK, NY / ACCESSWIRE / March 14, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more...
Source: https://incomestatements.info
Category: Stock Reports